Canino F, Barbolini M, De Giorgi U, Fontana T, et al. Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study. BMC Cancer 2024;24:735.
PMID: 38879498